Retrospective analysis of management of patients presenting with acute urinary retention due to benign prostatic hyperplasia: a hospital based study.
OBJECTIVE
To analyze current practice of management of acute urinary retention (AUR) in men above 40 years of age at B.P.Koirala Institute of Health Sciences, Nepal.


METHODS
A total of 68 patients (aged 50-91 years) presenting with indwelling catheter for AUR were included in the study. Because of lack of clear guideline and limited health care facility in our setup trial without catheter (TWOC) was given selectively depending mainly on preexisting symptoms. AUR presumed to be due to urinary tract infection received only antibiotic and others diagnosed of benign prostatic hyperplasia (BPH) received alpha 1 blocker prior to TWOC. TWOC was given 3-15 days after such treatment. Those satisfied without catheter for at least a week were considered successful TWOC.


RESULTS
The data was available for 68 patients (mean age 66.1 years). Of 15 patients treated with antibiotic alone, 11 (73.3 %) had successful TWOC. Of 57 with presumptive diagnosis of BPH, 68.9% (31 of 45) had successful TWOC. Mean age, symptom score and prostate volume were higher for patients with unsuccessful TWOC.


CONCLUSIONS
Selective TWOC may be imperative to minimize unnecessary suffering from AUR in less easily accessible health care facilities like ours. It may also reduce total cost of treatment.
Pandit
R K
RK
Department of Surgery, B.P. Koirala Institute of Health Sciences, Dharan, Nepal. rakeshkp1@yahoo.com
Agrawal
C S
CS
Chalise
P R
PR
Sapkota
G
G
D000208:Acute Disease; D000317:Adrenergic alpha-Antagonists / Q000627:therapeutic use; D000368:Aged; D000369:Aged, 80 and over; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D002408:Catheters, Indwelling; D003131:Combined Modality Therapy; D006801:Humans; D008297:Male; D008875:Middle Aged; D011470:Prostatic Hyperplasia / Q000150:complications*; D012189:Retrospective Studies; D016896:Treatment Outcome; D016055:Urinary Retention / Q000209:etiology* / Q000628:therapy*
D000317:Adrenergic alpha-Antagonists; D000900:Anti-Bacterial Agents